March 3, 2026Frontiers in Dementia2 citationsOpen Access

Microglial activation is raised in preclinical Alzheimer’s disease and associated with covert memory impairment

PKPernille Louise KjeldsenAarhus University LMLasse Stensvig MadsenAarhus University PPPeter Parbo

Puntos clave

Impaired memory test performance is evident in preclinical Alzheimer's disease and is linked to microglial activation, raising concerns about early cognitive risks.
In affected cases, raised microglial activation indicates underlying cognitive issues despite the absence of outward symptoms during assessment.
Microglial activation was measured in preclinical Alzheimer's patients without cognitive complaints, highlighting a need for further understanding of early changes.
These findings suggest potential strategies for early intervention in Alzheimer's disease, given the early signs of cognitive decline.

Resumen

Microglial activation was significantly raised in preclinical AD cases with no cognitive complaints and associated with impaired memory test performance. This suggests that microglial activation is present before overt clinical symptoms emerge and may be detrimental to cognition even at this early stage.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo